Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has provided an announcement.
Neurizon Therapeutics has announced that Managing Director and Chief Executive Officer Dr Michael Thurn has resigned and will step down from his executive duties on 16 March 2026, remaining through his notice period until July to support an orderly transition and continue as a Non-Executive Director during that time. The board credited Thurn with steering the company’s rebranding from PharmAust, advancing lead asset NUZ-001 through early clinical studies, strengthening regulatory engagement and partnerships, and securing entry into the HEALEY ALS Platform Trial.
To maintain leadership continuity, Chair Sergio Duchini will assume the role of Executive Chair on an interim basis, receiving additional remuneration of $30,000 per month while the company conducts a global search for a new CEO with the help of executive search firm Coulter Partners. Neurizon’s existing leadership team is expected to continue progressing its clinical and corporate programs on previously communicated timelines, signalling a focus on operational stability and ongoing execution despite the leadership change.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), with a strategy to accelerate access to effective ALS therapies while exploring broader neurodegenerative indications through international collaborations and rigorous clinical programs.
YTD Price Performance: 12.94%
Average Trading Volume: 580,910
Technical Sentiment Signal: Sell
Current Market Cap: A$67.07M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.